MS decreases the larger amplitude distribution in adult rats. by Jesús David Ayala-Rodríguez (17364296)

Data_Sheet_1_Immune and Neuroendocrine Trait and State Markers in Psychotic Illness: Decreased Kynurenines Marking Psychotic Exacerbations.docx by Livia De Picker (8319105)

“…</p><p>Conclusion: The acute psychotic state is marked by state-specific increases of immune markers and decreases in peripheral IDO pathway markers. …”

The classic univariate ROC analysis on the validation set of significant biomarker candidates. by Nguyen Ky Anh (17307349)

“…<p>The classic univariate ROC analysis on the validation set of significant biomarker candidates.</p>…”

(A) Auxiliary marking points to ensure complete and accurate seating of the prosthesis. by Long Li (6555)

Subjects:

Loss map of training set and validation set. by Weiwei Cheng (582223)

Cinacalcet administered early in the inactive phase markedly decrease parathyroid Ki-67 index. by Søren Egstrand (10906087)

Variables in training set and validation set. by Yongzhong Tang (9972779)

Subjects:

Validation set diagram. by Michael Morris (1820158)

A noxious temperature decrease without a prior increase produces a subtly larger decrease in pain intensity. by Benedict J. Alter (9745466)

PD-1 deficiency does not significantly impact the pathogen load and pathology following <i>S</i>. <i>japonicum</i> infection. by Liaoxun Lu (179293)

Subjects:

Significantly Enriched Pathways. by Jiyong Zhang (2498740)

Subjects:

Significance of FakeNET with k-fold validation. by Turki Aljrees (16715369)

IV-KAPhE performs well in cross-validation and significantly outperforms previously published methods on an external validation set. by Brandon M. Invergo (11179036)

Larger example of stimuli with cue relevant for Task 3. by Marcel F. Hinss (14675457)

The level of miRNA 221 in the myocardium of MIRI mice was decreased. by Hongyu Li (1332669)

Subjects:

Points represent regions where the cluster coefficient was significantly larger in HC compared to MCI, at sparsity level of 0.15. by Therese M. Gilligan (7460906)

Model performance on the validation set. by Lin Qi (128224)

Train and validation set description. by Yegor Bugayenko (15194643)

“…From a practical perspective, such a set of metrics is difficult to manage and companies, especially small ones, may feel overwhelmed and unable to select a viable subset of them. …”

Relationships between the ROC of training set and validation set. by Yongzhong Tang (9972779)

Subjects:

Comparison of clinical data in training set and validation set. by Han Wang (254423)